Valiant Laboratories Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 5,445,000 (50%) | — | ₹7,623 Cr |
| NII (HNI) | — | 1,633,500 (15%) | — | ₹2,287 Cr |
| Retail | — | 3,811,500 (35%) | — | ₹5,336 Cr |
| Σ Total | — | 10,890,000 (100%) | — | ₹152,460 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 105 | ₹14,700 |
| Retail (Max) | 13 | 1,365 | ₹191,100 |
| S-HNI (Min) | 14 | 1,470 | ₹205,800 |
| B-HNI (Min) | 67 | 7,035 | ₹984,900 |
Financial Statements Amount in Crore
| Metric | 31 Mar 2021 | 31 Mar 2022 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 184 | 293 | 339 |
| Profit After Tax | 31 | 28 | 29 |
| Net Worth | 89 | 71 | 100 |
| Total Assets | 106 | 182 | 213 |
| Total Borrowing | 0 | 61 | 59 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL) for part-financing its capital expenditure requirements in relation to the setting up of a manufacturing facility for specialty chemicals at Saykha Industrial Area, Bharuch, Bharuch, Gujarat (Proposed Facility). –
- Investment in VASPL for funding its working capital requirements. –
- General corporate purposes. –
Company Overview
Incorporated in 1980, Valiant Laboratories Limited is a pharmaceutical ingredient manufacturing company in India having focuses on manufacturing Paracetamol.
The company's manufacturing unit is located in Palghar, Maharashtra, spread across 2,000 sq. mts. of land with an aggregate annual total installed capacity of 9,000 MT per annum. Valiant Laboratories also has an R&D Facility, equipped with an analytical laboratory and infrastructure for developmental activities in existing products.
For the Fiscal 2023, Fiscal 2022 and Fiscal 2021, Valiant Laboratories revenue from operations was Rs. 3,339.10 million, Rs. 2,915.23 million and Rs. 1,823.69 million, respectively.
Valiant Laboratories Limited imports Para Amino Phenol, being the raw material for the manufacture of Paracetamol from China and Cambodia.
As of April 30, 2023, Valiant Laboratories has 86 employees.